• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 39-53 of 94 results

1017 Exhibit: Ex 1017 Jessen

Document IPR2021-01132, No. 1017-18 Exhibit - Ex 1017 Jessen (P.T.A.B. Jun. 17, 2021)
Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia Zimbabwe Apotex Exhibit 1017.002
Moreover, in these patients there exists a strong correlation between the increased fasting plasma glucose levels and the rate of hepatic glu­ cose production (reviewed in R.A. De Fronzo: Diabetes 37 (1988), 667 - 687; A. Consoli: Apotex Exhibit 1017.003
Several regulatory processes may influence these hypothalamic centres: Metabolic signals such as postprandial increases in plasma glucose and insulin; meal-induced gastric disten­ sion is another possible inhibitory factor.
For use within the present invention (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-pyrrolidine,D- tartrate may be formulated with a pharmaceutically acceptable carrier or excipient to provide a medicament for parenteral, oral, nasal, rectal, pulmonal, buccal, subdermal or intradermal or transdermal administration according to conventional methods.
Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pec­ tin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose.
cite Cite Document
Analyze

1003 Exhibit: Ex 1003 Gould CV

Document IPR2021-01132, No. 1003-3 Exhibit - Ex 1003 Gould CV (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1004 Exhibit: Ex 1004 927 PH

Document IPR2021-01132, No. 1004-4 Exhibit - Ex 1004 927 PH (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1011 Exhibit: Ex 1011 Wells

Document IPR2021-01132, No. 1011-12 Exhibit - Ex 1011 Wells (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1007 Exhibit: Ex 1007 550 PH Part 2 of 2

Document IPR2021-01132, No. 1007-8 Exhibit - Ex 1007 550 PH Part 2 of 2 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1005 Exhibit: Ex 1005 Coe

Document IPR2021-01132, No. 1005-5 Exhibit - Ex 1005 Coe (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1012 Exhibit: Ex 1012 Bighley

Document IPR2021-01132, No. 1012-13 Exhibit - Ex 1012 Bighley (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1008 Exhibit: Ex 1008 CA 2467490

Document IPR2021-01132, No. 1008-9 Exhibit - Ex 1008 CA 2467490 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1006 Exhibit: Ex 1006 US 6410550

Document IPR2021-01132, No. 1006-6 Exhibit - Ex 1006 US 6410550 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1009 Exhibit: Ex 1009 Berge

Document IPR2021-01132, No. 1009-10 Exhibit - Ex 1009 Berge (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1010 Exhibit: Ex 1010 Gould

Document IPR2021-01132, No. 1010-11 Exhibit - Ex 1010 Gould (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1016 Exhibit: Ex 1016 Nyqvist

Document IPR2021-01132, No. 1016-17 Exhibit - Ex 1016 Nyqvist (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1015 Exhibit: Ex 1015 Bastin

Document IPR2021-01132, No. 1015-16 Exhibit - Ex 1015 Bastin (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1020 Exhibit: Ex 1020 US 2870198

Document IPR2021-01132, No. 1020-21 Exhibit - Ex 1020 US 2870198 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1013 Exhibit: Ex 1013 Paulekuhn

Document IPR2021-01132, No. 1013-14 Exhibit - Ex 1013 Paulekuhn (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 >>